MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.690
+0.020
+1.20%
Opening 09:55 08/14 EDT
OPEN
1.720
PREV CLOSE
1.670
HIGH
1.770
LOW
1.690
VOLUME
121.15K
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
0.5600
MARKET CAP
78.32M
P/E (TTM)
-3.6699
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLSD stock price target is 5.60 with a high estimate of 8.00 and a low estimate of 3.000.

EPS

CLSD News

More
Clearside Biomedical shares are trading higher after the company reported Q2 EPS and sales results were up year over year. The company also announced the FDA has accepted its investigational new drug application for CLS-AX administered in Suprachoroidal Space.
Benzinga · 2d ago
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 3d ago
Clearside Biomedical shares are trading higher after the company reported Q2 EPS and sales results were up year over year. The company also announced the FDA has accepted its investigational new drug application for CLS-AX administered in Suprachoroidal Space.
Benzinga · 3d ago
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
Clearside Biomedical shares are trading higher after the company reported Q2 EPS and sales results were up year over year.
Benzinga · 3d ago
Clearside Biomedical Q2 EPS $(0.13) Up From $(0.15) YoY, Sales $354.00K Up From $45.00K YoY
Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $354.00 thousand
Benzinga · 3d ago
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX Administered in Suprachoroidal Space
Benzinga · 3d ago
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update
\- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - \- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - \- Engaged New Contract Manufacturer for XIPERE™ - \- Management to Host Webcast and Confere
GlobeNewswire · 3d ago

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About CLSD

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.
More

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.